Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCellular and Molecular
Open Access

Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors

Simona Dedoni, Luisa Marras, Maria C. Olianas, Angela Ingianni and Pierluigi Onali
Journal of Pharmacology and Experimental Therapeutics September 2019, 370 (3) 490-503; DOI: https://doi.org/10.1124/jpet.119.258129
Simona Dedoni
Laboratory of Cellular and Molecular Pharmacology, Section of Neurosciences, Department of Biomedical Sciences (S.D., M.C.O., P.O.) and Section of Microbiology, Department of Biomedical Sciences (L.M., A.I.), University of Cagliari, Cagliari, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Simona Dedoni
Luisa Marras
Laboratory of Cellular and Molecular Pharmacology, Section of Neurosciences, Department of Biomedical Sciences (S.D., M.C.O., P.O.) and Section of Microbiology, Department of Biomedical Sciences (L.M., A.I.), University of Cagliari, Cagliari, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria C. Olianas
Laboratory of Cellular and Molecular Pharmacology, Section of Neurosciences, Department of Biomedical Sciences (S.D., M.C.O., P.O.) and Section of Microbiology, Department of Biomedical Sciences (L.M., A.I.), University of Cagliari, Cagliari, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maria C. Olianas
Angela Ingianni
Laboratory of Cellular and Molecular Pharmacology, Section of Neurosciences, Department of Biomedical Sciences (S.D., M.C.O., P.O.) and Section of Microbiology, Department of Biomedical Sciences (L.M., A.I.), University of Cagliari, Cagliari, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierluigi Onali
Laboratory of Cellular and Molecular Pharmacology, Section of Neurosciences, Department of Biomedical Sciences (S.D., M.C.O., P.O.) and Section of Microbiology, Department of Biomedical Sciences (L.M., A.I.), University of Cagliari, Cagliari, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pierluigi Onali
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    VPA downregulates TrkB expression in RA-differentiated neuroblastoma cells. (A) SH-SY5Y cells were incubated for 24 hours with either vehicle or 1 mM VPA, and the expression of full length (TrkB-FL) and truncated (TrkB-T) isoforms of TrkB was analyzed by Western blot and normalized to actin levels. Values are the mean ± S.E.M. of six independent experiments. (B) Quantitative real-time RT-PCR analysis of TrkB mRNA in SH-SY5Y cells treated for 24 hours with either vehicle or 1 mM VPA. Values are the mean ± S.E.M. of three independent determinations. (C–E) SH-SY5Y cells were treated as in (A), and the expression of TrkA (C), TrkC (D), and p75NTR (E) was determined in cell lysates. (F and G) Kelly (F) and LAN-1 (G) cells were treated for 24 hours with either vehicle or VPA (1 mM). Cell lysates were then analyzed for TrkB expression. Values are the mean ± S.E.M. of four (Kelly) and seven (LAN-1) experiments. *P < 0.05; ***P < 0.001 vs. control (vehicle) by Student’s t test.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Time- and concentration-dependent inhibition of TrkB expression by VPA. (A) SH-SY5Y cells were incubated in the presence of 1 mM VPA for the indicated periods of time. Zero time samples were treated with vehicle and used as control. (B) SH-SY5Y cells were incubated for 24 hours in the presence of either vehicle or VPA at the indicated concentrations. Cell lysates were analyzed for TrkB expression. Values are the mean ± S.E.M. of four experiments. *P < 0.05; ***P < 0.001 vs. control (vehicle) by analysis of variance (ANOVA) followed by Newman-Keuls post hoc test.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    VPA reduces plasma membrane expression of TrkB. SH-SY5Y cells were treated with either vehicle or VPA (1 mM) for 24 hours. Cells were then exposed to the cell impermeant biotinylating agent sulfosuccinimidyl-6-(biotin-amido)hexanoate and solubilized proteins were precipitated by using streptavidin-conjugated agarose beads. The precipitate (surface protein) and total extract (cell lysate) were analyzed for TrkB by Western blot (A). TrkB levels in the surface protein preparation were normalized to pan-cadherin levels, a plasma membrane (membr) marker. Densitometric values are expressed as percent of control (vehicle) and are the mean ± S.E.M. of four experiments. (B) TrkB expression was analyzed by immunofluorescence (green color) in nonpermeabilized cells with an antibody directed against an extracellular domain of the receptor. Nuclei were stained in blue with 4′,6-diamidino-2phenylindole (DAPI). Values are the mean ± S.E.M. of four experiments. Scale bar, 25 µm. ***P < 0.001 vs. control (vehicle) by Student’s t test.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Inhibition of BDNF-induced TrkB activation and signaling by VPA. (A–D) SH-SY5Y cells were incubated for 24 hours with either vehicle or 1 mM VPA and then exposed for 5 minutes to either vehicle or 1 nM BDNF. Cell lysates were analyzed for the expression of phospho-Tyr706/707-TrkB (pTrkB), total TrkB-FL (A), phospho-Tyr783-PLCγ1 (pPLCγ1), total PLCγ1 (B), phospho-Thr308-Akt (pAkt), total Akt (C), phospho-Ser9-GSK-3β (pGSK-3β), and total GSK-3β (D). Values are the mean ± S.E.M. of four experiments. (E and F) SH-SY5Y cells were incubated for 24 hours with either vehicle or 1 mM VPA and then exposed for 5 minutes to either vehicle, 0.05 nM BDNF (BDNF 0.05), or 0.1 nM BDNF (BDNF 0.1). Cell lysates were analyzed for phospho-ERK1/2 (pERK1/2), total ERK1/2, phospho-Ser235/236-S6 ribosomal protein (pS6rp), and total S6 ribosomal protein (S6rp). Values are the mean ± S.E.M. of three experiments. (G and H) LAN-1 (G) and Kelly (H) cells were incubated for 24 hours with either vehicle or 1 mM VPA and then exposed for 5 minutes to either vehicle or 1 nM BDNF. Values are the mean ± S.E.M. of three experiments. *P < 0.05; ***P < 0.001 vs. control (vehicle); #P < 0.05; ###P < 0.001 vs. BDNF + vehicle by ANOVA followed by Newman-Keuls post hoc test.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    VPA curtails BDNF-induced proneurotrophic and antiapoptotic responses. (A) SH-SY5Y cells were preincubated for 24 hours with either vehicle or 1 mM VPA and then exposed for 48 hours to either vehicle or 1.0 nM BDNF. Cells were fixed and stained with an antiactin antibody (red color). Nuclei were stained in blue with DAPI. For each sample, the number of neurite-bearing cells was determined and calculated as percent of total cells. Values are the mean ± S.E.M. of three separate experiments. (B–E) Cells were preincubated for 24 hours with either vehicle, VPA 0.6 mM (VPA 0.6), or VPA 1.0 mM (VPA 1.0) and then exposed to either vehicle or 1 nM BDNF for 48 hours. Cell lysates were analyzed for the expression of MAP2 (B), synapsyn-1 (synap-1) (C), GluR1 (D), and postsynaptic density 95 (PSD95) (E). Values are the mean ± S.E.M. of four experiments. (F) SH-SY5Y cells were pretreated for 24 hours with either vehicle or 1 mM VPA and then incubated in serum-free medium in the absence and in the presence of 1 nM BDNF for 48 hours. Cells were fixed and analyzed by immunofluorescence for cleaved caspase 3 expression (green color). Cell nuclei were stained with DAPI. For each sample, the number of cleaved caspase 3-positive cells was determined and calculated as percent of total cells. Values are the mean ± S.E.M. of three experiments. (G) SH-SY5Y cells were treated as indicated in (F) and cell lysates were analyzed for cleaved PARP (cleav PARP) and uncleaved PARP (PARP). Values are the mean ± S.E.M. of three experiments. *P < 0.05; ***P < 0.001 vs. control (vehicle); #P < 0.05; ###P < 0.001 vs. BDNF alone by ANOVA followed by Newman-Keuls post hoc test.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    HDAC inhibitors and HDAC1 knockdown mimic the inhibitory effect of VPA on TrkB expression and signaling. (A–C) SH-SY5Y cells were incubated for 24 hours with either vehicle, 1 mM sodium butyrate, 300 nM trichostatin A (TSA), 10 µM MC1568 (A), 1 µM entinostat (B), or 40 nM romidepsin (C). Cell lysates were then analyzed for TrkB expression. Values are the mean ± S.E.M. of four experiments. *P < 0.05; ***P < 0.001 vs. the respective control (vehicle) by Student’s t test. (D) SH-SY5Y cells were incubated for 24 hours with either vehicle or 1 µM entinostat and then TrkB expression was analyzed by immunofluorescence (green color) in nonpermeabilized cells stained with an antibody directed against an extracellular domain of the receptor. Nuclei were stained in blue with DAPI. Images are representative of four independent experiments. Scale bar, 25 µm. (E and F) SH-SY5Y cells were incubated for 24 hours with either vehicle, 4 µM PCI-34051, 5 µM tubacin (E), or 1 mM valpromide (VPM) (F). Values are the mean ± S.E.M. of four experiments. (G and H) SH-SY5Y cells were preincubated for 24 hours with either vehicle, 300 nM TSA, 1 mM VPM (G), 1 mM sodium butyrate, or 10 µM MC1568 (H) and then exposed for 5 minutes to 1 nM BDNF. Values are the mean ± S.E.M. of three experiments. (I and J) SH-SY5Y cells were preincubated for 24 hours with either vehicle, 0.5 µM entinostat (ent 0.5), 1 µM entinostat (ent 1) (I), 20 nM romidepsin (romi 20), or 40 nM romidepsin (romi 40) (J) and then exposed for 5 minutes to 1 nM BDNF. Values are the mean ± S.E.M. of four experiments. ***P < 0.001 vs. control; #P < 0.05; ###P < 0.001 vs. BDNF + vehicle by ANOVA followed by Newman-Keuls post hoc test. (K and L) SH-SY5Y cells were transfected with either control siRNA or HDAC1 siRNA duplexes and cell lysates were analyzed for HDAC1, H3 acetyl-Lys9/Lys14 (Ac-H3), total H3 (K), and TrkB expression (L). Each lane was loaded with a sample of an independent transfection. Values are the mean ± S.E.M. of three experiments. *P < 0.05; ***P < 0.001 vs. control siRNA by Student’s t test.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Involvement of RUNX3 in VPA-induced downregulation of TrkB. (A) SH-SY5Y cells were incubated with 1 mM VPA for the indicated periods of time. Zero time samples were treated with vehicle and used as control. (B) Cells were treated for 24 hours with the indicated concentrations of VPA. Cell lysates were analyzed for the protein levels of RUNX3 and H3-acetyl-Lys9/Lys14 (Ac-H3). Values are the mean ± S.E.M. of four experiments. *P < 0.05; ***P < 0.001 vs. control (vehicle) by ANOVA followed by Newman-Keuls post hoc test. (C) SH-SY5Y cells were incubated with either vehicle or 1 mM VPA for 24 hours. Nuclear extracts were prepared and analyzed for RUNX3 and HDAC1 levels. Values are the mean ± S.E.M. of four experiments. ***P < 0.001 by Student’s t test. (D) SH-SY5Y cells transfected with either control siRNA or RUNX3 siRNA were incubated for 24 hours with either vehicle, 0.6 mM VPA (VPA 0.6), or 1 mM VPA (VPA 1.0). Cell lysates were then analyzed for RUNX3 and TrkB expression. Values are the mean ± S.E.M. of three experiments. ***P < 0.001 vs. control siRNA + vehicle; #P < 0.05; ###P < 0.001 vs. the corresponding value in control siRNA-treated group by Student’s t test. (E) SH-SY5Y cells were treated for 24 hours with either vehicle or 1 mM VPA. Cell lysates were analyzed for EZH2 protein levels. Values are the mean ± S.E.M. of four experiments. ***P < 0.001 vs. control (vehicle) by Student’s t test. (F) Cells were transfected with either control siRNA or HDAC1 siRNA duplexes and cell lysates were analyzed for HDAC1, EZH2, RUNX3, and TrkB protein levels. Values are the mean ± S.E.M. of three experiments. *P < 0.05; ***P < 0.001 vs. the corresponding value in control siRNA-treated group by Student’s t test. (G) Cells were treated for 24 hours with either vehicle, 1 µM DZNep (DZNep 1), or 5 µM DZNep (DZNep 5). Cell lysates were then analyzed for EZH2, RUNX3, and TrkB expression. Values are the mean ± S.E.M. of four experiments. *P < 0.05; ***P < 0.001 vs. control (vehicle) by Student’s t test.

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    VPA and entinostat downregulate TrkB expression and signaling in mouse primary cortical neurons. (A) Neuronal cultures were treated with either vehicle, 1 mM VPA, or 1 µM entinostat for 24 hours, and cell extracts were analyzed for the expression of TrkB isoforms. Values are the mean ± S.E.M. of three experiments. *P < 0.05; ***P < 0.001 vs. control (vehicle) by Student’s t test. (B and C) neurons were preincubated for 24 hours with either vehicle, 1 mM VPA, or 1 µM entinostat (ent) and then exposed for 5 minutes to either vehicle or 1 nM BDNF. Cell extracts were analyzed for phospho-Tyr706/707-TrkB (pTrkB), TrkB-FL, phospho-Akt (Thr308), and total Akt. Values are the mean ± S.E.M. of three experiments. ***P < 0.001 vs. control (vehicle); ##P < 0.01; ###P < 0.001 vs. BDNF + vehicle by ANOVA followed by Newman-Keuls post hoc test. (D–F) Neurons were treated as indicated in (A) and cell extracts were then analyzed for Ac-H3, total H3, EZH2, and RUNX3 levels. Values are the mean ± S.E.M. of three separate experiments. *P < 0.05; ***P < 0.001 vs. control (vehicle) by Student’s t test.

Additional Files

  • Figures
  • Data Supplement

    • Supplemental Figures -

      S1: Induction of TrkB expression by RA in LAN-1 and Kelly human neuroblastoma cells.

      S2: Effects of HDAC inhibitors on histone H3 acetylation in differentiated SH-SY5Y cells.

      S3: Effects of VPA and entinostat on RUNX3 and EZH2 expression in Kelly and LAN-1 human neuroblastoma cells.

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 370 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 370, Issue 3
1 Sep 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCellular and Molecular

Inhibition of TrkB Expression by Valproic Acid

Simona Dedoni, Luisa Marras, Maria C. Olianas, Angela Ingianni and Pierluigi Onali
Journal of Pharmacology and Experimental Therapeutics September 1, 2019, 370 (3) 490-503; DOI: https://doi.org/10.1124/jpet.119.258129

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleCellular and Molecular

Inhibition of TrkB Expression by Valproic Acid

Simona Dedoni, Luisa Marras, Maria C. Olianas, Angela Ingianni and Pierluigi Onali
Journal of Pharmacology and Experimental Therapeutics September 1, 2019, 370 (3) 490-503; DOI: https://doi.org/10.1124/jpet.119.258129
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Zebrafish Gstp1 drug response
  • Comparison of Piceatannol with Resveratrol
  • Aldosterone synthesis in the heart
Show more Cellular and Molecular

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics